Analyzing Pharma Bio Serv (PBSV) and Its Peers
Pharma Bio Serv (OTCMKTS: PBSV) is one of 27 publicly-traded companies in the “Management consulting services” industry, but how does it weigh in compared to its peers? We will compare Pharma Bio Serv to similar businesses based on the strength of its earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and dividends.
Pharma Bio Serv pays an annual dividend of $0.08 per share and has a dividend yield of 7.3%. Pharma Bio Serv pays out -133.3% of its earnings in the form of a dividend. As a group, “Management consulting services” companies pay a dividend yield of 1.6% and pay out 35.4% of their earnings in the form of a dividend. Pharma Bio Serv is clearly a better dividend stock than its peers, given its higher yield and lower payout ratio.
Pharma Bio Serv has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Pharma Bio Serv’s peers have a beta of 0.80, suggesting that their average stock price is 20% less volatile than the S&P 500.
Valuation and Earnings
This table compares Pharma Bio Serv and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pharma Bio Serv||$15.58 million||-$1.41 million||-18.33|
|Pharma Bio Serv Competitors||$976.33 million||$66.45 million||20.03|
Pharma Bio Serv’s peers have higher revenue and earnings than Pharma Bio Serv. Pharma Bio Serv is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
65.9% of shares of all “Management consulting services” companies are held by institutional investors. 51.6% of Pharma Bio Serv shares are held by insiders. Comparatively, 10.6% of shares of all “Management consulting services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Pharma Bio Serv and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pharma Bio Serv||-14.93%||0.49%||0.41%|
|Pharma Bio Serv Competitors||-20.74%||-17.30%||-21.36%|
This is a breakdown of recent ratings and recommmendations for Pharma Bio Serv and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pharma Bio Serv||0||0||0||0||N/A|
|Pharma Bio Serv Competitors||126||416||596||32||2.46|
As a group, “Management consulting services” companies have a potential upside of 16.91%. Given Pharma Bio Serv’s peers higher probable upside, analysts clearly believe Pharma Bio Serv has less favorable growth aspects than its peers.
Pharma Bio Serv Company Profile
Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm with a laboratory testing facility in Puerto Rico, the United States, Europe, and Brazil markets. It provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products in Puerto Rico, the United States, Europe, and Brazil. The company's technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. It also offers microbiological and chemical testing services through its lab; and technical trainings/seminars. The company markets its services through industry trade shows, professional conventions, industry publications, and seminars. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.
Receive News & Ratings for Pharma Bio Serv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Bio Serv and related companies with MarketBeat.com's FREE daily email newsletter.